Intravenous Tissue Plasminogen Activator in Stroke Mimics.

BACKGROUND The necessity for rapid evaluation and treatment of acute ischemic stroke with intravenous tPA (tissue-type plasminogen activator) may increase the risk of administrating tPA to patients presenting with noncerebrovascular conditions that closely resemble stroke (stroke mimics). However, there are limited data on thrombolysis safety in stroke mimics. METHODS AND RESULTS Using data from the Get With The Guidelines-Stroke Registry, we identified 72 582 patients with suspected ischemic stroke treated with tPA from 485 US hospitals between January 2010 and December 2017. We documented the use of tPA in stroke mimics, defined as patients who present with stroke-like symptoms, but after workup are determined not to have suffered from a stroke or transient ischemic attack, and compared characteristics and outcomes in stroke mimics versus those with ischemic stroke. Overall, 3.5% of tPA treatments were given to stroke mimics. Among them, 38.2% had a final nonstroke diagnoses of migraine, functional disorder, seizure, and electrolyte or metabolic imbalance. Compared with tPA-treated true ischemic strokes, tPA-treated mimics were younger (median 54 versus 71 years), had a less severe National Institute of Health Stroke Scale (median 6 versus 8), and a lower prevalence of cardiovascular risk factors, except for a higher prevalence of prior stroke/transient ischemic attack (31.3% versus 26.1%, all P<0.001). The rate of symptomatic intracranial hemorrhage was lower in stroke mimics (0.4%) as compared with 3.5% in ischemic strokes (adjusted odds ratio, 0.29; 95% CI, 0.17-0.50). In-hospital mortality rate was significantly lower in stroke mimics (0.8% versus 6.2%, adjusted odds ratio, 0.31; 95% CI, 0.20-0.49). Patients with stroke mimics were more likely to be discharged to home (83.8% versus 49.3%, adjusted odds ratio, 2.97; 95% CI, 2.59-3.42) and to ambulate independently at discharge (78.6% versus 50.6%, adjusted odds ratio, 1.86; 95% CI, 1.61-2.14). CONCLUSIONS In this large cohort of patients treated with tPA, relatively few patients who received tPA for presumed stroke were ultimately not diagnosed with a stroke or transient ischemic attack. The complication rates associated with tPA in stroke mimics were low. Despite the potential risk of administering tPA to stroke mimics, opportunity remains for continued improvement in the rapid and accurate diagnosis and treatment of ischemic stroke.

[1]  P. Lyden,et al.  Using the National Institutes of Health Stroke Scale: A Cautionary Tale , 2017, Stroke.

[2]  Eric E. Smith,et al.  Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non–Vitamin K Antagonist Oral Anticoagulants Before Stroke , 2017, Circulation.

[3]  Eric E. Smith,et al.  Use of Strategies to Improve Door-to-Needle Times With Tissue-Type Plasminogen Activator in Acute Ischemic Stroke in Clinical Practice: Findings from Target Stroke , 2017, Circulation. Cardiovascular quality and outcomes.

[4]  Eric E. Smith,et al.  Risks and Benefits Associated With Prestroke Antiplatelet Therapy Among Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator. , 2016, JAMA neurology.

[5]  A. Alexandrov,et al.  Safety of Intravenous Thrombolysis in Stroke Mimics: Prospective 5-Year Study and Comprehensive Meta-Analysis , 2015, Stroke.

[6]  Eric E. Smith,et al.  Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. , 2014, JAMA.

[7]  P. Lavados,et al.  Exclusion criteria for intravenous thrombolysis in stroke mimics: an observational study. , 2013, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[8]  Adrian F Hernandez,et al.  Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. , 2013, JAMA.

[9]  D. Leys,et al.  Safety of Thrombolysis in Stroke Mimics: Results From a Multicenter Cohort Study , 2013, Stroke.

[10]  M. Wintermark,et al.  Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2013, Stroke.

[11]  Eric E. Smith,et al.  A Risk Score for In‐Hospital Death in Patients Admitted With Ischemic or Hemorrhagic Stroke , 2013, Journal of the American Heart Association.

[12]  A. Luft,et al.  Different Pattern of Clinical Deficits in Stroke Mimics Treated with Intravenous Thrombolysis , 2012, European Neurology.

[13]  Eric E. Smith,et al.  Risk Score for Intracranial Hemorrhage in Patients With Acute Ischemic Stroke Treated With Intravenous Tissue-Type Plasminogen Activator , 2012, Stroke.

[14]  J. Masjuán,et al.  Stroke Mimics Treated with Thrombolysis: Further Evidence on Safety and Distinctive Clinical Features , 2012, Cerebrovascular Diseases.

[15]  Eric E. Smith,et al.  Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. , 2012, JAMA.

[16]  Eric E. Smith,et al.  Data quality in the American Heart Association Get With The Guidelines-Stroke (GWTG-Stroke): results from a national data validation audit. , 2012, American heart journal.

[17]  A. Meretoja,et al.  Stroke mimics and intravenous thrombolysis. , 2012, Annals of emergency medicine.

[18]  D. Leys,et al.  Intravenous thrombolytic therapy in patients with stroke mimics: baseline characteristics and safety profile , 2011, European journal of neurology.

[19]  Eric E. Smith,et al.  Improving Door-to-Needle Times in Acute Ischemic Stroke: The Design and Rationale for the American Heart Association/American Stroke Association's Target Stroke Initiative , 2011, Stroke.

[20]  A. Alexandrov,et al.  Safety and Outcomes of Intravenous Thrombolysis in Stroke Mimics: A 6-Year, Single-Care Center Study and a Pooled Analysis of Reported Series , 2011, Stroke.

[21]  Eric E. Smith,et al.  Risk Score for In-Hospital Ischemic Stroke Mortality Derived and Validated Within the Get With The Guidelines–Stroke Program , 2010, Circulation.

[22]  Gregory W Albers,et al.  Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials , 2010, The Lancet.

[23]  Swift or sure? , 2010, Neurology.

[24]  Eric E. Smith,et al.  Characteristics, Performance Measures, and In-Hospital Outcomes of the First One Million Stroke and Transient Ischemic Attack Admissions in Get With The Guidelines-Stroke , 2010, Circulation. Cardiovascular quality and outcomes.

[25]  K. Lee.  Get With the Guidelines–Stroke Is Associated With Sustained Improvement in Care for Patients Hospitalized With Acute Stroke or Transient Ischemic Attack , 2010 .

[26]  P. Fuhr,et al.  Thrombolysis in Stroke Mimics: Frequency, Clinical Characteristics, and Outcome , 2009, Stroke.

[27]  Li Liang,et al.  Get With the Guidelines–Stroke Is Associated With Sustained Improvement in Care for Patients Hospitalized With Acute Stroke or Transient Ischemic Attack , 2009, Circulation.

[28]  R. Silbergleit,et al.  Misdiagnosis of stroke in tissue plasminogen activator-treated patients: characteristics and outcomes. , 2003, Annals of emergency medicine.

[29]  J. Gurwitz,et al.  Risk for Intracranial Hemorrhage after Tissue Plasminogen Activator Treatment for Acute Myocardial Infarction , 1998, Annals of Internal Medicine.